Nocdurna (Desmopressin)

Desmopressin is a synthetic vasopressin analogue that selectively activates V2 receptors in the kidney collecting ducts. This triggers a cascade that increases cyclic AMP, leading to the insertion of aquaporin‑2 channels into the tubular membrane, which concentrates urine and retains water. It also stimulates endothelial release of von Willebrand factor and factor VIII, aiding haemostasis.

The dose of Nocdurna is individualized by the prescribing clinician based on the specific indication, patient age, renal function, and response to therapy. Dosage adjustments are made according to clinical guidelines and laboratory monitoring, and patients should follow the exact regimen provided by their healthcare professional.

Safety data for desmopressin in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers must evaluate each case carefully and discuss potential risks with the patient before initiating therapy.

To request Nocdurna, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Nocdurna (desmopressin) is a selective V2‑receptor agonist, offering a more targeted antidiuretic effect than non‑selective agents such as carbamazepine. Its sublingual formulation provides rapid absorption and convenient dosing, while also possessing haemostatic benefits not seen with traditional antidiuretic drugs.

Nocdurna tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Nocdurna is taken as a sublingual tablet. The tablet is placed under the tongue and allowed to dissolve completely without chewing or swallowing whole. Patients should avoid eating or drinking for a few minutes after administration to ensure optimal absorption.

The most serious risks include severe hyponatremia, which can cause seizures, coma, or cerebral edema, and water intoxication leading to significant fluid overload. Patients should be monitored for rapid weight gain, confusion, or neurological symptoms, and serum sodium should be checked regularly.

Nocdurna is contraindicated in patients with known hypersensitivity to desmopressin, uncontrolled hyponatremia, or severe renal impairment. Caution is also advised for individuals taking other antidiuretic agents, certain diuretics, or those with a history of water‑retention disorders.